Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) — Board Meeting

📢 Key Event
Appointment of Anil Kumar Matai as Independent Director

🔄 What Changed
Addition of a new independent director with extensive pharma leadership experience

🔮 What's Next
Subject to shareholder approval at upcoming meeting

💡 Investor Takeaway
The new director enhances governance expertise and may improve strategic decision-making.

Jagsonpal Pharmaceuticals announced the appointment of Anil Kumar Matai as an additional independent director effective June 25, 2026, for a five-year term subject to shareholder approval. The board approved the appointment during a meeting held on June 25, 2026, from 4:45 p.m. to 5:30 p.m. Mr. Matai brings over 35 years of experience in multinational pharmaceuticals, including leadership roles at Novartis India and Zydus Healthcare, and currently serves as Director General of OPPI. His appointment aims to strengthen governance and strategic oversight in the life sciences sector.

📄 View Original Announcement (PDF)

📊 Stock Analysis — JAGSNPHARM ✨ Ask AI About This